39% Revenue Surge, Guidance Hike, and $100M Buyback Fuel CareDx Q1 Beat
CDNA sits 99% above its 52-week low of $10.96.
Summary
CareDx reported a strong first quarter, with revenue rising 39% to $118 million, significantly surpassing analyst estimates of $104.03 million. Non-GAAP net income per share of $0.34 also comfortably beat the $0.13 consensus. Building on this momentum, the company raised its full-year 2026 revenue guidance to $447 million-$465 million and adjusted EBITDA guidance to $43 million-$57 million. Additionally, CareDx announced a new $100 million share repurchase program, signaling strong financial health and a commitment to shareholder returns. This robust performance and capital allocation strategy are highly material for the company, especially following its recent strategic divestiture of the Lab Products business.
At the time of this announcement, CDNA was trading at $21.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $10.96 to $23.24. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.